GALECTIN THERAPEUTICS INC — Director's Dealing 2016

Jan 22, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2016-01-20

Reporting Person: CALLICUTT JACK W (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-20	Stock option (right to buy)	$1.37	A	38000	Acquired	2026-01-20	Common Stock (38000)	Direct

Footnotes

F1: The options vest as follows: 25% immediately, and the remaining 75% in equal installments on a monthly basis over a period of three years.